表紙
市場調查報告書

先天性遺傳基因·染色體異常遺傳基因檢驗:開發平台分析

Inborn Gene or Chromosome Alterations - Medical Devices Pipeline Assessment, 2019

出版商 GlobalData 商品編碼 342293
出版日期 內容資訊 英文 498 Pages
訂單完成後即時交付
價格
Back to Top
先天性遺傳基因·染色體異常遺傳基因檢驗:開發平台分析 Inborn Gene or Chromosome Alterations - Medical Devices Pipeline Assessment, 2019
出版日期: 2019年12月15日內容資訊: 英文 498 Pages
簡介

本報告提供全球各國的企業·醫療機關等正在開發的先天性遺傳基因·染色體異常遺傳基因檢驗的相關產品 (檢查裝置·試劑等) 之開發中產品資訊相關分析,提供您臨床實驗/產品開發的整體進展,及各階段·各領域·各地區的詳細趨勢,各企業·各產品的詳細資訊 (臨床實驗的進展階段,開始/結束時期,認證預測等),近來的產品開發的動向·產業趨勢等資料,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 先天性遺傳基因·染色體異常 (變性) 轉動遺傳基因檢驗概要

第3章 開發中的產品

  • 開發中產品:各開發階段
  • 開發中產品:各地區
  • 開發中產品:各法規途徑
  • 開發中產品:各核審時期 (估計)
  • 現在進行中的臨床實驗

第4章 先天性遺傳基因·染色體異常遺傳基因檢驗:正在開發的開發中產品 (各企業)

  • 先天性遺傳基因·染色體異常遺傳基因檢驗的開發企業:開發中產品 (各開發階段)
  • 先天性遺傳基因·染色體異常遺傳基因檢驗:各開發階段的開發中產品一覽

第5章 先天性遺傳基因·染色體異常遺傳基因檢驗的開發企業·產品概要

  • AC-Gen Reading Life S.L.
    • 開發中產品及現在進行中的臨床實驗概要
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Ariosa Diagnostics, Inc.
  • Atomic International
  • Baylor College of Medicine
  • BCML GmbH
  • BioCeps (Inactive)
  • CardioDx, Inc.
  • Celera Corporation
  • Celula, Inc.
  • Children's Hospital Boston
  • China Medical Technologies, Inc.
  • Da An Gene Co., Ltd.
  • Dana-Farber Cancer Institute, Inc.
  • Epinex Diagnostics Incorporated
  • Genentech, Inc.
  • German Cancer Research Center
  • GILUPI Nanomedizin
  • Hadassah Medical Center
  • Helicos BioSciences Corporation
  • Illumina, Inc.
  • IntegraGen SA
  • Interleukin Genetics, Inc.
  • JS Genetics Inc.
  • Laboratory Corporation of America Holdings
  • Laval University
  • LifeCodexx AG
  • Maastricht University Medical Center
  • Massachusetts Eye and Ear Infirmary
  • Medical Research Council
  • Micromedic Technologies Ltd
  • Multiplicom N.V.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • National University of Singapore
  • NewGene Ltd
  • NX PharmaGen Inc.
  • Paragon Medical, Inc.
  • Population Diagnostics Inc.
  • Qiagen N.V.
  • Quantamerix
  • Sapien Biosciences
  • Seegene, Inc.
  • Sequenom, Inc.
  • Stanford University
  • The Johns Hopkins University
  • The Sheba Medical Center
  • The University of Utah
  • TrovaGene, Inc.
  • University of Colorado
  • University of Washington
  • VitaPath Genetics, Inc.
  • Xiamen Zeesan Biotech Co.,Ltd
  • Yale University

第6章 先天性遺傳基因·染色體異常遺傳基因檢驗:近來的市場趨勢

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0841EPD

GlobalData's Medical Devices sector report, "Inborn Gene or Chromosome Alterations - Medical Devices Pipeline Assessment, 2019" provides an overview of Inborn Gene or Chromosome Alterations currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Inborn Gene or Chromosome Alterations pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Inborn Gene or Chromosome Alterations under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Inborn Gene or Chromosome Alterations and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Inborn Gene or Chromosome Alterations under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1 List of Tables 14
  • 1.2 List of Figures 26

2 Introduction 27

  • 2.1 Inborn Gene or Chromosome Alterations Overview 27

3 Products under Development 28

  • 3.1 Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development 28
  • 3.2 Inborn Gene or Chromosome Alterations - Pipeline Products by Territory 29
  • 3.3 Inborn Gene or Chromosome Alterations - Pipeline Products by Regulatory Path 30
  • 3.4 Inborn Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date 31
  • 3.5 Inborn Gene or Chromosome Alterations - Ongoing Clinical Trials 32

4 Inborn Gene or Chromosome Alterations - Pipeline Products under Development by Companies 33

  • 4.1 Inborn Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development 33
  • 4.2 Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development 39

5 Inborn Gene or Chromosome Alterations Companies and Product Overview 47

6 Inborn Gene or Chromosome Alterations- Recent Developments 282

7 Appendix 484

List of Tables

  • Table 1: Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development 28
  • Table 2: Inborn Gene or Chromosome Alterations - Pipeline Products by Territory 29
  • Table 3: Inborn Gene or Chromosome Alterations - Pipeline Products by Regulatory Path 30
  • Table 4: Inborn Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date 31
  • Table 5: Inborn Gene or Chromosome Alterations - Ongoing Clinical Trials 32
  • Table 6: Inborn Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development 33
  • Table 7: Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development 39
  • Table 8: AbaStar MDx Inc Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 9: Molecular Diagnostic Test - Bipolar Disorder - Product Status 47
  • Table 10: Molecular Diagnostic Test - Bipolar Disorder - Product Description 47
  • Table 11: Molecular Diagnostic Test - Depression - Product Status 48
  • Table 12: Molecular Diagnostic Test - Depression - Product Description 48
  • Table 13: Molecular Diagnostic Test - Parkinson's Disease - Product Status 48
  • Table 14: Molecular Diagnostic Test - Parkinson's Disease - Product Description 49
  • Table 15: Molecular Diagnostic Test - Schizophrenia - Product Status 49
  • Table 16: Molecular Diagnostic Test - Schizophrenia - Product Description 49
  • Table 17: Adipomics Inc Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 18: Diagnostic Test - Type 2 Diabetes - Product Status 50
  • Table 19: Diagnostic Test - Type 2 Diabetes - Product Description 50
  • Table 20: Advanced Genomic Technology, LLC Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 21: Blood MicroRNA-Based AD Diagnostic And Prognostic Kit - Product Status 51
  • Table 22: Blood MicroRNA-Based AD Diagnostic And Prognostic Kit - Product Description 51
  • Table 23: Agena Bioscience Inc Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 24: Sensigene Trisomy 21 Laboratory Developed Test - Product Status 52
  • Table 25: Sensigene Trisomy 21 Laboratory Developed Test - Product Description 52
  • Table 26: Alexion Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 53
  • Table 27: SmartPanel - Product Status 53
  • Table 28: SmartPanel - Product Description 53
  • Table 29: Amarantus Bioscience Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 30: Diagnostic Test - IFN-Beta Resistance - Product Status 54
  • Table 31: Diagnostic Test - IFN-Beta Resistance - Product Description 54
  • Table 32: Amity University Pipeline Products & Ongoing Clinical Trials Overview 55
  • Table 33: Prenatal Screening Kit - Product Status 55
  • Table 34: Prenatal Screening Kit - Product Description 55
  • Table 35: Arrayit Corporation Pipeline Products & Ongoing Clinical Trials Overview 56
  • Table 36: PDx Pre-Symptomatic Test - Product Status 56
  • Table 37: PDx Pre-Symptomatic Test - Product Description 56
  • Table 38: Asuragen Inc Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 39: Diagnostic Test - Neurodegenerative Disorders - Product Status 57
  • Table 40: Diagnostic Test - Neurodegenerative Disorders - Product Description 57
  • Table 41: Signature CF Expand - Product Status 58
  • Table 42: Signature CF Expand - Product Description 58
  • Table 43: Augusta University Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 44: SUMO Gene Test - Type 1 Diabetes - Product Status 59
  • Table 45: SUMO Gene Test - Type 1 Diabetes - Product Description 59
  • Table 46: AutoGenomics Inc Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 47: DNA Guided Diagnostic Test - Cardiovascular Disease - Product Status 60
  • Table 48: DNA Guided Diagnostic Test - Cardiovascular Disease - Product Description 60
  • Table 49: DNA Guided Diagnostic Test - Diabetes - Product Status 61
  • Table 50: DNA Guided Diagnostic Test - Diabetes - Product Description 61
  • Table 51: DNA Guided Diagnostic Test - Obesity - Product Status 61
  • Table 52: DNA Guided Diagnostic Test - Obesity - Product Description 62
  • Table 53: INFINITI Factor II-V And MTHFR Assay - Product Status 62
  • Table 54: INFINITI Factor II-V And MTHFR Assay - Product Description 62
  • Table 55: INFINITI FMF Assay - Product Status 63
  • Table 56: INFINITI FMF Assay - Product Description 63
  • Table 57: INFINITI MTHFR Assay - Product Status 63
  • Table 58: INFINITI MTHFR Assay - Product Description 64

List of Figures

  • Figure 1: Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development 28
  • Figure 2: Inborn Gene or Chromosome Alterations - Pipeline Products by Territory 29
  • Figure 3: Inborn Gene or Chromosome Alterations - Pipeline Products by Regulatory Path 30
  • Figure 4: Inborn Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date 31
  • Figure 5: Inborn Gene or Chromosome Alterations - Ongoing Clinical Trials 32
Back to Top